当前位置: X-MOL 学术BioEssays › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
What deubiquitinating enzymes, oncogenes, and tumor suppressors actually do: Are current assumptions supported by patient outcomes?
BioEssays ( IF 3.2 ) Pub Date : 2021-01-07 , DOI: 10.1002/bies.202000269
Sophie Gregoire-Mitha 1, 2 , Douglas A Gray 1, 2
Affiliation  

Context can determine whether a given gene acts as an oncogene or a tumor suppressor. Deubiquitinating enzymes (DUBs) regulate the stability of many components of the pathways dictating cell fate so it would be expected that alterations in the levels or activity of these enzymes may have oncogenic or tumor suppressive consequences. In the current review we survey publications reporting that genes encoding DUBs are oncogenes or tumor suppressors. For many DUBs both claims have been made. For such “double agents,” the effects of gain or loss of function will depend on the overall status of a complex of molecular signaling networks subject to extensive crosstalk. As the TGF‐β paradox makes clear context is critical in cell fate decisions, and the disconnect between experimental findings and patient survival outcomes can in part be attributed to disparities between culture conditions and the microenvironment in vivo. Convincing claims for oncogene or tumor suppressor roles require the documentation of gene alterations in patient samples; survival curves are alone inadequate.

中文翻译:

去泛素化酶、癌基因和肿瘤抑制因子的实际作用:当前的假设是否得到患者结果的支持?

上下文可以确定给定的基因是作为致癌基因还是抑癌基因。去泛素化酶 (DUB) 调节决定细胞命运的途径的许多成分的稳定性,因此预计这些酶的水平或活性的改变可能会产生致癌或抑制肿瘤的后果。在当前的审查中,我们调查了报道编码 DUB 的基因是癌基因或肿瘤抑制基因的出版物。对于许多配音,这两种说法都已提出。对于这种“双重代理”,功能获得或丧失的影响将取决于受到广泛串扰的分子信号网络复合体的整体状态。由于 TGF-β 悖论明确背景对于细胞命运决定至关重要,实验结果与患者生存结果之间的脱节部分归因于培养条件和体内微环境之间的差异。致癌基因或肿瘤抑制作用的令人信服的声明需要记录患者样本中的基因改变;生存曲线本身是不够的。
更新日期:2021-03-15
down
wechat
bug